Navigation Links
CareFusion Reports Third Quarter Rise in Revenue, Earnings
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today reported results for the three and nine months ended March 31, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

"Our business performed well in the quarter, driving revenue and operating earnings growth year-over-year and expanding margins through a favorable product mix and disciplined expense control," said Kieran Gallahue, chairman and CEO. "Our earnings for the quarter outperformed our internal expectations, giving us confidence to raise the lower end of our adjusted EPS guidance and narrow the range to $1.60 to $1.65. Additionally, we continue to make progress in our efforts to optimize our product portfolio. We recently completed the divestiture of two businesses and acquired Vestara, expanding our core Pyxis medication management portfolio to include technology that enables hospitals to automate the segregation of pharmaceutical waste."

CareFusion's reported results compare to the three and nine month periods ended March 31, 2010.

Results from the company's International Surgical Products (ISP) business, which had been included in the Medical Technologies and Services segment and was divested in April 2011, have been classified as discontinued operations in the accompanying financial tables. Reported results for continuing operations and comparisons to prior periods exclude the historical results of the ISP business.

Third Quarter ResultsRevenue for the third quarter of fiscal 2011 increased 4 percent to $867 million on a reported basis and 3 percent on a constant currency basis, driven primarily by increased sales in the Infusion, Infection Prevention and Dispensing businesses. Operating income was $146 million and income from continuing operations was $86 million, or $0.38 per diluted share. Excluding nonrecurring items, adjusted operating income increased $51 million to $155 million and adjusted income from continuing operations increased $41 million to $94 million, or $0.42 per diluted share. The adjusted tax rate for the quarter was 31.7 percent.

Operating expenses, including selling, general and administrative (SG&A), research and development (R&D), restructuring and acquisition integration charges and gain on the sale of assets totaled $301 million, or 35 percent of total revenue. Excluding $9 million of nonrecurring items, adjusted operating expenses totaled $292 million, or 34 percent of total revenue. Adjusted SG&A expenses were $253 million and R&D investments totaled $39 million.

Critical Care TechnologiesRevenue for the Critical Care Technologies segment increased 5 percent to $661 million driven by Infusion product sales, including core growth and a contribution from the May 2010 acquisition of Medegen, and an increase in Dispensing sales. These increases were offset by an expected decrease in Respiratory sales due to a weak post H1N1 environment. Segment profit increased 49 percent to $115 million, and adjusted segment profit increased 43 percent to $129 million.

Medical Technologies and ServicesRevenue for the Medical Technologies and Services segment decreased 1 percent to $206 million, driven by the loss of revenue from the company's May 2010 divestiture of the Research Services business, which was essentially offset by increased sales from the Infection Prevention and Medical Specialties businesses. Net of this divestiture, revenue growth would have been 8 percent. Segment profit increased 78 percent to $16 million, and adjusted segment profit increased 86 percent to $26 million.

Nine-Month ResultsRevenue for the first nine months of fiscal 2011 increased 1 percent to $2.56 billion. Operating income increased to $347 million and income from continuing operations was $195 million, or $0.87 per diluted share. Excluding nonrecurring items, adjusted operating income increased $47 million to $423 million and adjusted income from continuing operations increased $32 million to $253 million, or $1.13 per diluted share.

Operating expenses totaled $958 million or 37 percent of total revenue. Excluding $76 million of nonrecurring items, adjusted operating expenses totaled $882 million, or 34 percent of total revenue. Adjusted SG&A expenses were $767 million, and R&D investments totaled $115 million.

Critical Care TechnologiesRevenue for the Critical Care Technologies segment increased 2 percent to $1.96 billion. Segment profit increased 3 percent to $298 million, or 9 percent to $357 million on an adjusted basis.

Medical Technologies and ServicesRevenue for the Medical Technologies and Services segment decreased 2 percent to $602 million. Segment profit was even with the prior year at $34 million, and increased 35 percent to $66 million on an adjusted basis.

Fiscal 2011 Outlook CareFusion reaffirmed its fiscal 2011 revenue guidance of low single digit growth over fiscal 2010 revenue of $3.5 billion. In addition, the company narrowed its outlook for adjusted diluted EPS from continuing operations for fiscal 2011 to a range of $1.60 to $1.65, the upper end of its previously provided guidance range of $1.58 to $1.65. The guidance is based on an assumed diluted weighted average outstanding share count of approximately 225 million.

Conference CallCareFusion will host a conference call today at 2 p.m. PDT (5 p.m. EDT) to discuss earnings results for the third quarter fiscal 2011.

To access the call and corresponding slide presentation, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Investors and other interested parties may also access the call by dialing (800) 901-5247 within the U.S. or (617) 786-4501 from outside the U.S., and use the access code 55257170. A replay of the conference call will be available from 5 p.m. PDT (8 p.m. EDT) on May 5 through 8:59 p.m. PDT (11:59 p.m. EDT) on May 12 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 Internationally and using the access code 91057852.

About CareFusion CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AirLife™, AVEA® and LTV® series of ventilators and respiratory products, ChloraPrep® skin prep products, MedMined™ services for data mining surveillance, V. Mueller® and Snowden-Pencer® surgical instruments and NeuroCare diagnostic products. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

Use of Non-GAAP Financial Measures by CareFusion CorporationThis CareFusion news release presents non-GAAP financial measures that exclude certain amounts, as follows: “adjusted operating expenses”, “adjusted SG&A expenses” and “adjusted operating income”, which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring gain on the sale of assets; “adjusted income from continuing operations”, “adjusted diluted earnings per share from continuing operations” and “adjusted effective tax rate”, which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets, and nonrecurring tax items; and “adjusted segment profit”, which excludes nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.

The most directly comparable measure for these non-GAAP financial measures are operating expenses, SG&A expenses, operating income, income from continuing operations, diluted earnings per share from continuing operations, effective tax rate, and segment profit (the most comparable GAAP measures). The company has included below unaudited adjusted financial information for the quarter and nine month periods ended March 31, 2011 and 2010, which includes a reconciliation of GAAP to non-GAAP financial measures.

In addition, CareFusion presents the non-GAAP financial measure “adjusted diluted earnings per share from continuing operations” on a forward-looking basis. The most directly comparable forward-looking GAAP measure for the company is diluted earnings per share from continuing operations. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion’s future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding CareFusion’s financial condition and results of operations is included as Exhibit 99.3 to CareFusion’s report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2011.

Cautions Concerning Forward-looking StatementsThe CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of May 5, 2011. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)Quarter Ended Nine Months Ended March 31,March 31,(in millions, except per share amounts)2011201020112010Revenue

$

867

$

837

$

2,564

$

2,542Cost of Products Sold4204231,2591,263Gross Margin4474141,3051,279Selling, General and Administrative Expenses263285805834Research and Development Expenses3942115115Restructuring and Acquisition Integration Charges141537Gain on the Sale of Assets(15)-(15)-Operating Income14686347323Interest Expense and Other, Net 19276289Income Before Income Tax12759285234Provision for Income Tax417290123Income (Loss) from Continuing Operations86(13)195111Discontinued OperationsImpairment/Loss from the Disposal of Discontinued Businesses, Net of Tax(40)-(40)(8)Income (Loss) from the Operations of Discontinued Businesses, Net of Tax(1)4439Income (Loss) from Discontinued Operations, Net of Tax(41)4(36)31Net Income (Loss)

$

45

$

(9)

$

159

$

142Per Share Amounts: (1)Basic Earnings (Loss) per Common Share:Continuing Operations

$

0.39

$

(0.06)

$

0.88

$

0.50Discontinued Operations

$

(0.18)

$

0.02

$

(0.16)

$

0.14Basic Earnings (Loss) per Common Share

$

0.20

$

(0.04)

$

0.71

$

0.64Diluted Earnings (Loss) per Common Share:Continuing Operations

$

0.38

$

(0.06)

$

0.87

$

0.50Discontinued Operations

$

(0.18)

$

0.02

$

(0.16)

$

0.14Diluted Earnings (Loss) per Common Share

$

0.20

$

(0.04)

$

0.71

$

0.64Weighted-Average Number of Common Shares Outstanding:Basic223.0221.6222.6221.4Diluted (2) 225.6221.6224.6222.7____________(1)Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from the table may not equal the per share amounts presented. (2)Dilutive shares outstanding equal basic shares outstanding for the quarter ended March 31, 2010 as the impact would be anti-dilutive. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended March 31, 2011DiscontinuedNonrecurring(in millions, except per common share amounts)GAAP Operations (1)Items (2)Adjusted (3)Revenue (4)$

867

$

-

$

-

$

867Cost of Products Sold420--420Gross Margin447-447Selling, General and Administrative Expenses263-(10)253Research and Development Expenses39--39Restructuring and Acquisition Integration Charges 14-(14)-Gain on the Sale of Assets(15)-15-Operating Income146-9155Interest Expense and Other, Net 19--19Income Before Income Tax127-9136Provision for Income Tax41-142Income from Continuing Operations86-894Discontinued OperationsImpairment Loss from Discontinued Businesses, Net of Tax(40)40--Loss from the Operations of Discontinued Businesses, Net of Tax(1)1--Loss from Discontinued Operations, Net of Tax(41)41---Net Income

$

45

$

41

$

8

$

94Per Share Amounts: (5)Basic Earnings per Common Share

$

0.20

$

0.18

$

0.04

$

0.42Diluted Earnings per Common Share

$

0.20

$

0.18

$

0.03

$

0.42Weighted-Average Number of Common Shares Outstanding:Basic223.0223.0223.0223.0Diluted 225.6225.6225.6225.6Effective Tax Rate32.7%n/a17.9%31.7%____________(1)Reflects the impact of the divestiture of the International Surgical Products (ISP) business.(2)Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets and nonrecurring tax items.  (3)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(4)Revenues increased $30 million for the quarter ended March 31, 2011 compared to 2010, or a $27 million increase on a constant currency basis.(5)Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Nine Months Ended March 31, 2011DiscontinuedNonrecurring(in millions, except per common share amounts)GAAP Operations (1)Items (2)Adjusted (3)Revenue (4)$

2,564

$

-

$

-

$

2,564Cost of Products Sold1,259--1,259Gross Margin1,305--1,305Selling, General and Administrative Expenses805-(38)767Research and Development Expenses115--115Restructuring and Acquisition Integration Charges 53-(53)-Gain on the Sale of Assets(15)-15-Operating Income347-76423Interest Expense and Other, Net 62--62Income Before Income Tax285-76361Provision for Income Taxes90-18108Income from Continuing Operations195-58253Discontinued OperationsImpairment Loss from Discontinued Businesses, Net of Tax(40)40--Income from the Operations of Discontinued Businesses, Net of Tax4(4)--Loss from Discontinued Operations, Net of Tax(36)36--Net Income

$

159

$

36

$

58

$

253Per Share Amounts: 5Basic Earnings per Common Share

$

0.71

$

0.16

$

0.26

$

1.14Diluted Earnings per Common Share

$

0.71

$

0.16

$

0.26

$

1.13Weighted-Average Number of Common Shares Outstanding:Basic222.6222.6222.6222.6Diluted224.6224.6224.6224.6Effective Tax Rate31.7%n/a23.8%30.0%____________(1)Reflects the impact of the divestiture of the International Surgical Products (ISP) business.(2)Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets and nonrecurring tax items.  (3)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(4)Revenues increased $22 million for the nine months ended March 31, 2011 compared to 2010, or a $26 million increase on a constant currency basis.(5)Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended March 31, 2010DiscontinuedNonrecurring(in millions, except per common share amounts)GAAP Operations (1)Items (2)Adjusted (3)Revenue$

837

$

-

$

-

$

837Cost of Products Sold423--423Gross Margin414--414Selling, General and Administrative Expenses285-(17)268Research and Development Expenses42--42Restructuring and Acquisition Integration Charges 1-(1)-Operating Income86-18104Interest Expense and Other, Net 27--27Income Before Income Tax59-1877Provision for Income Tax72-(48)24Income (Loss) from Continuing Operations(13)-6653Discontinued OperationsIncome from the Operations of Discontinued Businesses, Net of Tax4(4)--Income from Discontinued Operations, Net of Tax4(4)--Net Income (Loss)

$

(9)

$

(4)

$

66

$

53Per Share Amounts: (4)Basic Earnings (Loss) per Common Share

$

(0.04)

$

(0.02)

$

0.30

$

0.24Diluted Earnings (Loss) per Common Share

$

(0.04)

$

(0.02)

$

0.30

$

0.24Weighted-Average Number of Common Shares Outstanding:Basic221.6221.6221.6221.6Diluted (5)221.6221.6221.6221.6Effective Tax Rate122.8%n/a(258.3)%31.7%____________(1)Reflects the impact of the divestiture of the International Surgical Products (ISP) business.(2)Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring charges related to a tax reserve adjustment ($58 million) for uncertain tax positions and nonrecurring tax items associated with the other non-tax adjustments. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.(3)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(4)Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. (5)Dilutive shares outstanding equal basic shares outstanding for the quarter ended March 31, 2010 as the impact would be anti-dilutive.CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Nine Months Ended March 31, 2010DiscontinuedNonrecurring(in millions, except per common share amounts)GAAP Operations (1)Items (2)Adjusted (3)Revenue$

2,542

$

-

$

-

$

2,542Cost of Products Sold1,263--1,263Gross Margin1,279--1,279Selling, General and Administrative Expenses834-(46)788Research and Development Expenses115--115Restructuring and Acquisition Integration Charges 7-(7)-Operating Income323-53376Interest Expense and Other, Net 89-(22)67Income Before Income Tax234-75309Provision for Income Tax123-(35)88Income from Continuing Operations111-110221Discontinued OperationsLoss from the Disposal of Discontinued Businesses, Net of Tax(8)8--Income from the Operations of Discontinued Businesses, Net of Tax39(39)--Income from Discontinued Operations, Net of Tax31(31)--Net Income

$

142

$

(31)

$

110

$

221Per Share Amounts: (4)Basic Earnings per Common Share

$

0.64

$

(0.14)

$

0.50

$

1.00Diluted Earnings per Common Share

$

0.64

$

(0.14)

$

0.50

$

0.99Weighted-Average Number of Common Shares Outstanding:Basic221.4221.4221.4221.4Diluted222.7222.7222.7222.7Effective Tax Rate52.8%n/a(46.4)%28.6%____________(1)Reflects the impact of (a) removing certain businesses that manufacture and sell surgical and exam gloves, surgical drapes and apparel and fluid management products in the U.S. market that were previously part of the Clinical and Medical Products segment of Cardinal Health and were retained by Cardinal Health upon the spinoff, (b) the divestiture of the Company’s audiology business and (c) the divestiture of the International Surgical Products (ISP) business.(2)Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring charges related to the bridge loan entered into in connection with the spinoff, nonrecurring charges related to a tax reserve adjustment ($58 million) for uncertain tax positions and nonrecurring tax items associated with the other non-tax adjustments. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.(3)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(4)Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended March 31, 2011Nonrecurring(in millions)GAAP Items (1)Adjusted (2)Critical Care TechnologiesRevenue$

661

$

-

$

661Operating Income (3)11514129Medical Technologies and ServicesRevenue$

206

$

-

$

206Operating Income (3)161026Nine Months Ended March 31, 2011Nonrecurring(in millions)GAAP Items (1)Adjusted (2)Critical Care TechnologiesRevenue$

1,962

$

-

$

1,962Operating Income (3)29859357Medical Technologies and ServicesRevenue$

602

$

-

$

602Operating Income (3)343266Quarter Ended March 31, 2010Nonrecurring(in millions)GAAP (4)Items (1)Adjusted (2)Critical Care TechnologiesRevenue$

629

$

-

$

629Operating Income771390Medical Technologies and ServicesRevenue$

208

$

-

$

208Operating Income 9514Nine Months Ended March 31, 2010Nonrecurring(in millions)GAAP (4)Items (1)Adjusted (2)Critical Care TechnologiesRevenue$

1,928

$

-

$

1,928Operating Income28938327Medical Technologies and ServicesRevenue$

614

$

-

$

614Operating Income341549____________(1)Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.(2)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(3)The $15 million gain on the sale of assets associated with the March 2011 divestiture of our OnSite Services business has not been allocated to segment results for the quarter and nine months ended March 31, 2011.(4)Previously reported amounts have been adjusted to reflect discontinued operations.
'/>"/>

SOURCE CareFusion Corp.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition
2. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
3. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
4. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
5. CareFusion Moves First Quarter Earnings Announcement to November 5
6. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
7. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
8. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
9. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
10. CareFusion Will Host an Earnings Conference Call on Feb. 9 to Discuss the Results for the Second Quarter of Fiscal 2010
11. FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ...
(Date:2/5/2016)... Dehaier Medical Systems Ltd. (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, today announced its corporate ... the Company,s resources to develop its mobile health ... focus more on its major businesses. As of ...
(Date:2/5/2016)... Site Profile: --> ... The Speech Recognition People, announced their latest primary healthcare case study ... reduce turnaround times and to save the practice money. ... 2013 Challenge: --> ,- Wirral CCG ,- ... Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... ... Love is in the air at King Kullen! The local grocer is ... staple for Valentine’s Day is a must-have, and can be picked up with all ... are long-stem roses available, but also other flower bouquets, elegantly wrapped and ready to ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... , ... Stuart Bentkover, MD, FACS is thrilled to announce the ... effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to ... has been approved by the Food and Drug Administration (FDA) as a safe and ...
Breaking Medicine News(10 mins):